Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244


Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.

Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N.

J Hepatol. 2005 Dec;43(6):1013-20. Epub 2005 Jun 29.


Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions.

Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V, Garcia-Iglesias T, Hernandez-Flores G, Del Toro-Arreola S.

BMC Cancer. 2008 Jan 21;8:16. doi: 10.1186/1471-2407-8-16.


Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR.

Cancer Res. 2005 Jul 15;65(14):6321-9.


Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma.

Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC, Xia JC.

Chin J Cancer. 2013 Mar;32(3):141-8. doi: 10.5732/cjc.012.10025. Epub 2012 Jun 14.


The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection.

Suárez-Alvarez B, López-Vázquez A, Díaz-Molina B, Bernardo-Rodríguez MJ, Alvarez-López R, Pascual D, Astudillo A, Martínez-Borra J, Lambert JL, González S, López-Larrea C.

Transplantation. 2006 Aug 15;82(3):354-61.


HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S.

Blood. 2005 Jan 1;105(1):251-8. Epub 2004 Aug 24.


Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.

Kloss M, Decker P, Baltz KM, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih HR.

J Immunol. 2008 Nov 15;181(10):6711-9.


BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.

Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX, Steinle A, Charron D, Dombret H, Toubert A.

J Immunol. 2006 Apr 15;176(8):5108-16.


Human tumor-derived exosomes down-modulate NKG2D expression.

Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z.

J Immunol. 2008 Jun 1;180(11):7249-58.


Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection.

Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Suzuki T, Miyagi T, Hayashi N.

J Immunol. 2003 Nov 15;171(10):5423-9.


Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.

Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A.

Blood. 2003 Aug 15;102(4):1389-96. Epub 2003 Apr 24.


Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection.

Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, Spies T, Miyagi T, Suzuki T, Sasaki Y, Hayashi N.

J Immunol. 2003 Feb 1;170(3):1249-56.


Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system.

Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE.

Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):159-70. Epub 2007 Feb 26. Review.


Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma.

Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miyagi T, Hiramatsu N, Kanto T, Kasugai T, Katayama K, Kato M, Hayashi N.

Cancer Sci. 2008 Aug;99(8):1643-9. doi: 10.1111/j.1349-7006.2008.00859.x.


Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.

Song H, Kim J, Cosman D, Choi I.

Cell Immunol. 2006 Jan;239(1):22-30. Epub 2006 Apr 21.


NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors.

Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, Kubin M, Soria JC, Chouaib S, Mami-Chouaib F.

J Immunol. 2005 Nov 1;175(9):5790-8.


The soluble major histocompatibility complex class I-related chain A protein reduced NKG2D expression on natural killer and T cells from patients with prolactinoma and non-secreting pituitary adenoma.

Ma L, Li G, Su Y, He Q, Zhang C, Zhang J.

J Clin Neurosci. 2010 Feb;17(2):241-7. doi: 10.1016/j.jocn.2009.05.023. Epub 2009 Dec 31.


Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.

Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR.

Clin Cancer Res. 2008 Jun 1;14(11):3520-8. doi: 10.1158/1078-0432.CCR-07-4744.


IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.

Kloess S, Huenecke S, Piechulek D, Esser R, Koch J, Brehm C, Soerensen J, Gardlowski T, Brinkmann A, Bader P, Passweg J, Klingebiel T, Schwabe D, Koehl U.

Eur J Immunol. 2010 Nov;40(11):3255-67. doi: 10.1002/eji.201040568. Epub 2010 Oct 27.


Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.

Schrama D, Terheyden P, Otto K, Kämmerer U, Bröcker EB, Lühder F, Cosman D, Andersen MH, Becker JC.

Eur J Immunol. 2006 Jan;36(1):65-72.

Supplemental Content

Support Center